Biotech startup Enveda has closed a $311 million Series E funding round, doubling its valuation to $2 billion. The company utilizes artificial intelligence to discover novel therapeutic compounds derived from natural sources such as plants and microbes, moving beyond traditional laboratory synthesis.
Founded in 2019 by Viswa Colluru, Enveda stands out by successfully advancing AI-discovered drug candidates into human clinical trials. Current pipelines include treatments targeting severe skin conditions and therapies designed to maintain weight loss following GLP-1 cessation, addressing major modern health challenges.
This substantial capital injection highlights growing investor confidence in applying machine learning to drug discovery. The fresh funds will directly support ongoing clinical trials, marking a significant step toward validating AI’s practical impact in pharmacology.
- Raised $311 million in Series E funding with a $2 billion valuation
- Uses AI to discover medicines derived from plants and microbes
- Advancing AI-discovered drug candidates into human clinical trials
- Developing treatments for skin conditions and weight management
Sources:
